Looking ahead, Ernst & Young expects the biopharmaceutical industry to continue the emphasis on partnerships and bolt-on acquisitions over company acquisitions seen in 2021, only perhaps at greater volume. The rationale for partnerships and bolt-ons simply is better than for large-scale M&A as biopharmas look to bolster their pipelines and portfolios against expected mid-decade patent cliff issues that are expected to drive down compound annual growth rates, the firm’s 2022 EY M&A Firepower Report asserts.
EY: Don’t Expect Mega-Mergers To Return, But ‘Never Say Never’
EY Predicts Continued Emphasis On Bolt-On Deals, Partnerships In 2022
Firm’s annual biopharma firepower report notes there were no mega-mergers in 2021 and the conditions continue to make smaller deals and partnerships a better risk proposition.
More from Deals
• By
Plus deals involving Elix/PRISM, Rege/Syros, Kaken/KalVista, Dr. Reddy’s/Aurigene/Edity, Nissan Chemical/Sanwa, Lupin/Renascience, Shionogi/Link Medicine, Abbisko/Merck & Co., Ono/Reborna and Apollomics/LaunXp.
• By
Cancer assets drove the highest percentage of biopharma alliance dealmaking in 2024, tripling the frequency of the next highest therapeutic category, neurology.
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.
More from Business
• By
A brand new R&D center in Massachusetts and a giant manufacturing site for its future obesity drugs are among the key investments in the US.
• By
The CEO of a South Korean state-run drug R&D support fund urges the renewal of the initiative as it increasingly focuses on new modalities and novel targets.
• By
Roivant president Eric Venker was named CEO of Immunovant to guarantee execution of the development plan for IMVT-1402 in six indications, now including Sjögren’s disease and cutaneous lupus erythematosus.